North America Regional Plenary

IGCS19-0247

48

VARIATIONS IN ENDOMETRIAL CANCER RISK AND HISTOLOGIC DISTRIBUTION BY CARIBBEAN NATIVITY

¹M Schlumbercht*, ¹S George, ²A Pinto, ¹M Huang, ¹B Slomovitz, ³T Koru-Sengul.
¹Sylvester Comprehensive Cancer Center, Division of Gynecologic Oncology, Miami, USA;
²University of Miami, Department of Pathology, Miami, USA; ³University of Miami, Department of Public Health Sciences, Miami, USA

10.1136/ijgc-2019-IGCS.48

Objectives Prior data suggest that within subpopulations of racial and ethnic minorities, endometrial cancer (EC) risk varies. Nativity as mediator of risk has been poorly studied. Our objective was to determine if Caribbean nativity influences EC risk and presentation.

Methods Using the Florida Cancer Data System (FCDS), we identified women diagnosed with EC from 1981–2013. Demographics and pathologic factors were abstracted. Caribbean nativity included countries of both African and Hispanic lineage. Statistical analyses were performed using logistic regression and chi-square, with statistical significance at $p < 0.05$.

Results Of the 23,690 women in the FCDS identified with EC, 840 had Caribbean nativity. Among Caribbean immigrants with EC, a higher proportion had type II histologies compared to US natives (35.6% vs. 27.5%, $p < 0.01$), with very high prevalence seen among Haitian (54.2%, $p < 0.01$) and Jamaican (47.1%, $p < 0.01$) women. In comparison to US-born women, uterine serous carcinoma was more prevalent in women from Guyana (22.2% vs. 6.5%, $p = 0.03$) and Jamaica (13.8% vs. 6.5%, $p = 0.001$), with carcinosarcoma more prevalent in women from Haiti (13.5% vs. 4.6%, $p < 0.01$) and Jamaica (13.8% vs. 4.6%, $p < 0.01$). More Caribbean immigrants presented with distant disease (10.1% vs. 6.9%, $p < 0.01$). Relative to US natives, significant increases in type II EC risk were seen in women born in Haiti (OR 3.08 [2.06–4.62], $p < 0.01$) and Jamaica (OR 2.32 [1.66–3.25], $p < 0.01$).

Conclusions Women of Jamaican and Haitian birthplace have increased risks of type II EC compared to US-born women. Caribbean natives also have a higher prevalence of type II histologies. Effect of nativity on EC warrants further study.

IGCS19-0350

49

CIRCULATING CELL-FREE TUMOUR DNA FOR SURVEILLANCE OF ENDOMETRIAL AND OVARIAN CARCINOMA

¹A Lum, ¹S Lam, ¹M Nazeran, ¹W Yang, ¹J Senz, ²R Hernandez, ²S Malikic, ²M McConechy, ³DG Huntsman, ⁴J McAlpine*. ¹University of British Columbia, Pathology, Vancouver, Canada; ²Contextual Genomics, Bioinformatics, Vancouver, Canada; ³University of British Columbia and BC Cancer Agency, Pathology, Vancouver, Canada; ⁴University of British Columbia and BC Cancer Agency, Gynecology/Gynecologic Oncology, Vancouver, Canada

10.1136/ijgc-2019-IGCS.49

Objectives We sought to determine the feasibility and characterize the extinction kinetics of circulating cell-free tumor DNA (cfDNA) testing in endometrial and ovarian carcinomas (ECs, OCs) using a clinically-approved commercially-available assay.

Methods Women with suspected EC/OC undergoing surgery were consented for tissue and plasma sampling including pre-operative and serial post-operative draws. Tumour tissue and patient-matched buffy coat was extracted for DNA and sequenced for somatic mutations using FINDIT™ panel assay. Plasma samples were extracted for cfDNA and sequenced using FOLLOWIT™, Illumina platform, and analyzed using Contextual Genomics's QUALITY NEXUS analysis pipelines. Low-frequency variants were confirmed by digital droplet PCR.

Results 44 individuals had sufficient tissue and follow-up for inclusion; 24 ECs (13 endometrioid, 10 high-grade serous (HGS), 1 clear cell(CC)), 18 OCs (17 HGS 1, CC), and 2 synchronous endometrial and ovarian carcinomas. Eight ECs and 15 OC cases were advanced stage (II-IV) with residual disease in 2 ECs and 5 OCs, 8 recurrence events and 3 deaths recorded. Compliance with plasma sampling was high(>95%) when requested in hospital or at routine surveillance visits but dropped to 68% for 'extra' study-associated visits. Analysis to date reveals cfDNA was detectable in pre-operative samples of 19 individuals (9 ECs, 10 OCs including 4 early stage) and 6/10 tested post-operatively. Normalization of conventional tumour markers post-operatively took a median of 3mo in contrast to rapid loss of detectable cfDNA.

Conclusions cfDNA testing is feasible and may enhance surveillance of endometrial and ovarian carcinomas by reflecting i) volume of disease pre-/post-operatively, ii) response to therapy, and/or iii) recurrence.

IGCS19-0481

50

AGE, HISTOLOGY AND STAGE PREDICT SURVIVAL FOLLOWING ADJUVANT CHEMOTHERAPY AND RADIATION VERSUS RADIATION ALONE IN HIGH-RISK ENDOMETRIAL CANCER: A STUDY BASED ON PORTEC-3 CRITERIA

^{1,2}Y Casabianca*, ^{1,3}C Tian, ⁴M Powell, ⁵B Winterhoff, ⁶JK Chan, ²CD Shriver, ⁷CA Hamilton, ⁷GL Maxwell, ^{1,2,3}KM Darcy. ¹Uniformed Services University of the Health Sciences, Gynecologic Cancer Center of Excellence, Bethesda, USA; ²Uniformed Services University of the Health Sciences, John P Murtha Cancer Center Research Program, Bethesda, USA; ³Henry Jackson Foundation for the Advancement of Military Medicine- Inc., Women's Health Integrated Research Center, Amundale, USA; ⁴Washington University St Louis, Gynecologic Oncology, St Louis, USA; ⁵University of Minnesota, Gynecologic Oncology, Minneapolis, USA; ⁶Palo Alto Medical Foundation- California Pacific Medical Center- Sutter Health, Gynecologic Oncology, San Francisco, USA; ⁷Inova Fairfax Hospital and Inova Sar Cancer Institute, Gynecologic Oncology, Falls Church, USA

10.1136/ijgc-2019-IGCS.50

Objectives Evaluate the impact of age, stage and histology on survival in high-risk endometrial cancer (EC) following treatment with chemotherapy and radiation (CTRT) vs. radiation alone (RT).

Methods Eligible patients were diagnosed with high-risk EC from 2004–2014 in the National Cancer Database based on PORTEC-3 criteria and treated with pelvic beam radiation and/or radioactive implants. The CTRT group also received multiple-agent chemotherapy. A propensity score approach controlled for differences in clinical factors. Survival was evaluated using weighted Kaplan-Meier and Cox model analyses with interaction testing.

Abstract 50 Figure 1 Survival distributions and adjusted hazard ratio (HR) and 95% confidence interval (CI) for CTRT vs. RT

Results There were 10,009 women in the CTRT group and 10,006 in the RT group. After balancing, a 4.9% improvement in 5-year survival and a 15% drop in the adjusted risk of death was observed following treatment with CTRT *vs.* RT ($P<0.0001$). The survival benefit and reduction in the risk of death associated with CTRT *vs.* RT alone varied by age at diagnosis, stage and/or histology (figure 1, $P<0.0001$ for each interaction test) with the largest benefits at age ≥ 70 *vs.* <70 years old, with stage III *vs.* stage I/II disease and in serous/clear cell carcinoma *vs.* endometrioid carcinoma. CTRT was associated with a 20% increased risk of death in patients <70 years old with stage I/II endometrioid EC ($P<0.0001$).

Conclusions Age, stage and histology merit consideration when selecting adjuvant therapy for high-risk EC patients based on a study in 20,015 women.

IGCS19-0373

51

IN VITRO AND IN VIVO ACTIVITY OF SACITUZUMAB GOVITECAN, IN OVARIAN CANCER

¹E Perrone*, ¹S Lopez, ¹B Zeibek, ¹S Bellone, ¹L Zammataro, ¹A Manzano, ¹E Bonazzoli, ¹P Manara, ²G Scambia, ¹A Santin. ¹Yale University, Obstetrics- Gynecology- and Reproductive Sciences, New Haven, USA; ²Universita' Cattolica del Sacro Cuore, Department of Women's and Children's Health, Rome, Italy

10.1136/ijgc-2019-IGCS.51

Objectives Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, the active metabolite of